Navigation Links
No difference in death rates among patients exposed to common rheumatoid arthritis drugs
Date:8/7/2012

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Swedenthe first to compare mortality rates among patients treated with individual TNF inhibitorsis now available in Arthritis & Rheumatism, a journal published by Wiley on behalf of the American College of Rheumatology (ACR).

RA is a chronic, autoimmune disease characterized by inflammation in the joints that causes pain, tenderness and swelling. The World Health Organization estimates that RA affects up to one percent of individuals worldwide, with more than one million Americans diagnosed with the disease according to the ACR. Rheumatologists recommend early intervention with biologic disease modifying anti-rheumatic drugs (DMARDs) such as TNF inhibitors to slow disease progression, improve function, and prevent disability.

In Sweden nearly 15% of RA patients are prescribed TNF inhibitors. The present study examined the mortality rates in RA patients exposed to adalimumab, etanercept, or infliximab. "Understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing RA," said lead author Dr. Julia Fridman Simard with the Clinical Epidemiology Unit at Karolinska Institute in Stockholm, Sweden.

Researchers linked data from the Swedish Biologics Register (ARTIS), a comprehensive database of patients initiating first-ever biologic therapy for rheumatic diseases, and information from national Swedish registers that included data such as all-cause mortality, demographics, and RA characteristics. Between 2003 and 2008, 1,609 patients with RA initiated treatment with adalimumab, 2,686 with etanercept, and 2,027 with infliximab as their first ever biologic DMARD.

There were more than 19,000 person-years of follow-up during the five-year study period during which time 211 patients died (3.3%). "While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with RA," concludes Dr. Simard.


'/>"/>
Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Study finds significant skull differences between closely linked groups
2. Mayo Clinic study links healthy muscle mass to healthy bones, finds differences by gender
3. Pre-season fitness makes no difference to risk of injury
4. Love Knows No Gender Difference
5. Racial differences in diabetes diagnostic thresholds
6. Higher-spending hospitals have fewer deaths for emergency patients
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Cancer Diagnosis May Raise Odds for Suicide, Heart Attack Death
9. Death From Accidental Injuries Among Kids Drops 30%: CDC
10. Opioids associated with highest risk of death
11. Study reveals major funding shortfall and high death rates for emergency laparotomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 27, 2017 , ... ... an overview on laser diffraction analysis as a tool to characterize particle size ... and potential to obtain improved results and novel scientific findings. It describes methods ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... March 2014. The company had 800 customers and 2,250 RCEs at the time ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, ... announce an upgrade to the company's Yelp listing. Bay Area residents struggling from ... diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... call for entries to the 7th Edition of International Social Design Awards. ... Design Professionals, Product Designers, System Designers, Governments and Institutions worldwide with realized projects ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , February 24, 2017 Following ... Israel , s ... $ 250 M w ound care ... file s BST for inclusion in ... national healthcare reimbursement system   E-QURE Corp. ...
(Date:2/24/2017)... and Markets has announced the addition of the "Hemophilia Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Hemophilia ... market? What are the unit prices and annual treatment ...
(Date:2/24/2017)... HILL, N.C. , Feb. 24, 2017 /PRNewswire/ ... are exploring ways to increase their self-service capabilities ... Health Care Providers (HCPs). New research ... many pharma organizations have developed self-service website portals ... electronically.  This is just one of many findings ...
Breaking Medicine Technology: